Suzhou Basecare Medical (HKG:2170) forecasts revenue to increase between 42% to 47% to between 295 million yuan and 305 million yuan in 2024 from 208 million yuan in 2023, according to a Monday filing with the Hong Kong Exchange.
The foreseen rise in revenue is attributable to higher sales following the purchase of BMX Holdco, as well as other sales and purchase agreements for reproductive health products, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.